Disproportionality Analysis of Acute Kidney Injury Reports Associated with Sacubitril/Valsartan (ARNI) in the Japanese Adverse Drug Event Report Database
Drugs - Real World Outcomes · 28.10.2026
DOI: 10.1007/s40801-026-00593-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs - Real World Outcomes, online erschienen am 28.10.2026. Verfasst von Kazuya Urashima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Japan Community Healthcare Organization Osaka Minato Central Hospital, Osaka, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Prescriptions of angiotensin receptor neprilysin inhibitor (ARNI) have increased in recent years; however, few pharmacovigilance studies have investigated acute kidney injury (AKI) reporting associated with ARNI. This study evaluated the disproportionate AKI reporting associated with ARNI in the Japanese Adverse Drug Event Report (JADER) database, compared AKI reporting between reports involving ARNI and valsartan, and explored the factors associated with AKI reporting among reports involving ARNI.
Methods
Reports published in JADER between April 2020 and August 2023 were analyzed. AKI was identified using the narrow and broad scope Preferred Terms of the Standardized MedDRA Query (SMQ) “acute renal failure” (SMQ:20000003). The reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated for ARNI and valsartan. Multivariable logistic regression analyses were performed to estimate adjusted RORs (aRORs) for sex, age, heart failure (HF), diabetes mellitus, chronic kidney disease (CKD), concomitant diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs). An additional adjusted analysis directly compared AKI reports between ARNI and valsartan.
Results
A disproportionality signal for AKI was identified in the reports involving ARNI (ROR 7.11, 95% CI 6.27–8.07). Multivariable logistic regression showed that HF (aROR 1.68, 95% CI 1.22–2.31; p = 0.002) and CKD (aROR 2.17, 95% CI 1.60–2.93; p < 0.001) were independently associated with increased AKI reporting among reports involving ARNI. In the adjusted direct comparison, reports involving ARNI had higher odds of AKI reporting than those involving valsartan (aROR 2.03, 95% CI 1.50–2.74).
Conclusions
Disproportionate AKI reporting signals were identified in reports involving ARNI in the JADER database. HF and CKD were independently associated with increased AKI reporting after adjustment. These findings have provided additional pharmacovigilance evidence regarding ARNI-associated AKI in Japan and should be interpreted in light of the inherent limitations of spontaneous reporting data.
Autor:innen und Institutionen
- Department of Pharmacy, Japan Community Healthcare Organization Osaka Minato Central Hospital, Osaka, Japan.
- Department of Pharmacotherapeutics and Toxicology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Department of Pharmacy, Japan Community Healthcare Organization Yamato Koriyama Hospital, Yamatokoriyama, Japan.
- Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohtani University, Tondabayashi, Japan.
- Department of Pharmacy, Kansai Electric Power Hospital, Osaka, Japan.
- Department of Pharmacy, Osaka City General Hospital, Osaka, Japan.
Zitieren
APA
Urashima, K., Ueda, T., Urashima, Y., Tamura-Takaori, M., Fujimoto, A., Tanaka, S., Kohda, Y., Kitazawa, F., & Kato, R. (2026). Disproportionality Analysis of Acute Kidney Injury Reports Associated with Sacubitril/Valsartan (ARNI) in the Japanese Adverse Drug Event Report Database. Drugs - Real World Outcomes. https://doi.org/10.1007/s40801-026-00593-3
Vancouver
Urashima K, Ueda T, Urashima Y, Tamura-Takaori M, Fujimoto A, Tanaka S, et al. Disproportionality Analysis of Acute Kidney Injury Reports Associated with Sacubitril/Valsartan (ARNI) in the Japanese Adverse Drug Event Report Database. Drugs - Real World Outcomes. 2026. doi:10.1007/s40801-026-00593-3
BibTeX
@article{Urashima2026,
author = {Urashima, Kazuya and Ueda, Tooru and Urashima, Yoko and Tamura-Takaori, Mayuko and Fujimoto, Ayumi and Tanaka, Saori and Kohda, Yuka and Kitazawa, Fumiaki and Kato, Ryuji},
title = {Disproportionality Analysis of Acute Kidney Injury Reports Associated with Sacubitril/Valsartan (ARNI) in the Japanese Adverse Drug Event Report Database},
journal = {Drugs - Real World Outcomes},
year = {2026},
doi = {10.1007/s40801-026-00593-3}
}
EUVIMED